Christopher Sweeney Named Executive Director, Intellectual Property
Read about Christopher Sweeney Named Executive Director, Intellectual Property
England et al. (2024) “Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model” NPJ Vaccines.
DOI: 10.1038/s41541-024-00901-4
Read about England et al. (2024) “Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model” NPJ Vaccines.
Smith et al. (2024) “Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice” Nature Communications.
DOI: 10.1038/s41467-024-49332-8
Read about Smith et al. (2024) “Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice” Nature Communications.
Parhiz et al. (2024) “Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system” Molecular Therapy Nucleic Acids.
DOI: 10.1016/j.omtn.2024.102175
Read about Parhiz et al. (2024) “Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system” Molecular Therapy Nucleic Acids.
Montoya et al. (2024) “mRNA-LNP vaccine-induced CD8+ T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies” Molecular Therapy.
DOI: 10.1016/j.ymthe.2024.04.019
Read about Montoya et al. (2024) “mRNA-LNP vaccine-induced CD8+ T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies” Molecular Therapy.
Furey et al. (2024) “Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus” Nature Communications.
DOI: 10.1038/s41467-024-48555-z
Read about Furey et al. (2024) “Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus” Nature Communications.
Wiehe et al. (2024) “Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction” Cell Host & Microbe.
DOI: 10.1016/j.chom.2024.04.006
Read about Wiehe et al. (2024) “Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction” Cell Host & Microbe.
Acuitas Poster Presentations at ASGCT Annual Meeting
Read about Acuitas Poster Presentations at ASGCT Annual Meeting
Nong et al. (2024) “Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke” Molecular Therapy.
DOI: 10.1016/j.ymthe.2024.03.004
Read about Nong et al. (2024) “Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke” Molecular Therapy.
Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024
Read about Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024
Tafech et al. (2024) “Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions” Advanced Healthcare Materials.
DOI: 10.1002/adhm.202304525
Read about Tafech et al. (2024) “Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions” Advanced Healthcare Materials.
Tilsed et al. (2024) “IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation” PNAS.
DOI: 10.1073/pnas.2319856121
Read about Tilsed et al. (2024) “IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation” PNAS.